
Maze Therapeutics, Inc.: updates and filings
Price
$32.32
November 19, 2026Market cap $1.8B
What Ploutos Investor adds for Maze Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 2 fiscal years, from 2025
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 9, 2026next Feb 11, 2027
A rough estimate from when it has reported before, which has varied. The company announces the date itself.
November 2026
August 2026
May 2026
April 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 9, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 9, 2026Results of operationsForm8-K
- Oct 16, 2026Material agreement entered, unregistered sale of sharesForm8-K
- Aug 17, 2026Officer or director change, Regulation FD disclosureForm8-K
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 11, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 11, 2026Results of operationsForm8-K
- Jul 29, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Jun 10, 2026Shareholder voteForm8-K
- May 22, 2026Officer or director changeForm8-K
- May 15, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 13, 2026FilingFormEFFECT
- May 12, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 12, 2026Results of operationsForm8-K
- May 12, 2026FilingFormPOS AM
- Apr 28, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 28, 2026Additional annual meeting materialFormDEFA14A
- Apr 28, 2026Annual meeting proxy statementFormDEF 14A
- Apr 22, 2026Other material eventsForm8-K
- Apr 1, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Mar 25, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Mar 25, 2026Results of operations, officer or director change, Regulation FD disclosureForm8-K
- Feb 13, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Feb 13, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 9, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 9, 2026 | 8-K | Results of operations | Document |
| Oct 16, 2026 | 8-K | Material agreement entered, unregistered sale of shares | Document |
| Aug 17, 2026 | 8-K | Officer or director change, Regulation FD disclosure | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 11, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 11, 2026 | 8-K | Results of operations | Document |
| Jul 29, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Jun 10, 2026 | 8-K | Shareholder vote | Document |
| May 22, 2026 | 8-K | Officer or director change | Document |
| May 15, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 13, 2026 | EFFECT | Filing | Document |
| May 12, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 12, 2026 | 8-K | Results of operations | Document |
| May 12, 2026 | POS AM | Filing | Document |
| Apr 28, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 28, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 28, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Apr 22, 2026 | 8-K | Other material events | Document |
| Apr 1, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Mar 25, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Mar 25, 2026 | 8-K | Results of operations, officer or director change, Regulation FD disclosure | Document |
| Feb 13, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Feb 13, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jun 21, 2024.
The full analysis
What do Maze Therapeutics's filings show?
The filings are where every one of Maze Therapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.